Ireland
--:--IST
Priya Life Science Clinical trial register
Trackers› Clinical trials› Illinois
Clinical trial register · United States · industry-sponsored

Clinical Trials in Illinois, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9148 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 21 Nov 2026, 03:16 UTC
9148
Studies in scope
industry-sponsored, all four open statuses
4975
Recruiting now
open to new participants
2181
Lead sponsors
across recruiting studies
Top states
California 232 Florida 174 Arizona 113 Illinois 109 Georgia 104

Trials with a site in Illinois

109 of 9148 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Not yet open
AstraZeneca
Phase 2
250
California, Colorado, Connecticut, Florida, Georgia, Illinois, South Carolina, Texas
2026-11-30
Recruiting
AstraZeneca
Phase 3
750
Arizona, California, Colorado, Florida, Georgia, Illinois, Kentucky, Massachusetts
2026-09-24
Recruiting
AstraZeneca
Phase 3
1,330
Arkansas, California, Florida, Hawaii, Illinois, Iowa, Maryland, Michigan
2026-09-15
Recruiting
AstraZeneca
Phase 3
2,800
Alabama, Arizona, Arkansas, California, District of Columbia, Florida, Georgia, Illinois
2026-09-01
Recruiting
AstraZeneca
Phase 3
1,072
Arizona, California, Florida, Illinois, Indiana, Maryland, Massachusetts, Michigan
2026-08-31
Recruiting
AstraZeneca
Phase 3
500
California, Florida, Georgia, Illinois, Maryland, Missouri, Nevada, New Jersey
2026-08-24
Recruiting
AstraZeneca
Phase 3
1,500
Alabama, Arizona, Arkansas, California, Florida, Georgia, Illinois, Iowa
2026-08-20
Recruiting
AstraZeneca
Phase 3
2,500
Alabama, Arizona, California, Connecticut, Florida, Georgia, Illinois, Iowa
2026-08-19
Recruiting
AstraZeneca
Phase 3
600
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois
2026-08-12
Recruiting
AstraZeneca
Phase 3
915
Arkansas, California, Illinois, Massachusetts, Missouri, Nebraska, New York, Ohio
2026-07-16
Recruiting
Retinal Fundus Imaging and OCT Imaging for Ocular Detection of ATTR-CM
NCT07690436Transthyretin Amyloid Cardiomyopathy
AstraZeneca
Observational
500
California, Florida, Illinois, Massachusetts, Oregon, Tennessee
2026-07-08
Active, closed
AstraZeneca
Phase 1/2
164
California, Illinois, Kansas, Missouri, Nebraska
2026-07-08
Recruiting
AstraZeneca
Phase 3
1,200
Alabama, Arizona, California, Connecticut, Florida, Georgia, Idaho, Illinois
2026-07-06
Recruiting
AstraZeneca
Phase 3
900
Arizona, California, Florida, Illinois, Massachusetts, Michigan, Minnesota, Missouri
2026-07-06
Recruiting
AstraZeneca
Phase 3
2,000
Alabama, Arkansas, California, Florida, Georgia, Illinois, Indiana, Iowa
2026-07-06
Recruiting
AstraZeneca
Phase 3
750
Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois, Iowa
2026-06-26
Recruiting
AstraZeneca
Phase 3
150
California, Georgia, Illinois, Kentucky, Nevada, South Dakota, Tennessee, Texas
2026-06-15
Active, closed
AstraZeneca
Phase 2
326
California, Colorado, District of Columbia, Florida, Illinois, Massachusetts, Missouri, New York
2026-06-11
Recruiting
A Phase IIb Study to Evaluate AZD8965 in Participants With IPF.
NCT07652658Idiopathic Pulmonary Fibrosis (IPF)
AstraZeneca
Phase 2
359
Alabama, Arizona, California, Colorado, Florida, Georgia, Idaho, Illinois
2026-06-11
Recruiting
AstraZeneca
Observational
2,150
Arizona, Arkansas, California, Florida, Georgia, Illinois, Kansas, Maryland
2026-05-06
Recruiting
AstraZeneca
Phase 3
420
California, Colorado, Connecticut, Illinois, Kansas, Kentucky, Maryland, Massachusetts
2026-05-05
Recruiting
AstraZeneca
Phase 3
670
Alabama, Arizona, California, Colorado, Florida, Illinois, Louisiana, Maine
2026-05-04
Recruiting
AstraZeneca
Phase 3
245
Alabama, Arizona, California, Florida, Illinois, Indiana, Louisiana, Maryland
2026-04-13
Recruiting
AstraZeneca
Phase 3
508
Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Illinois
2026-02-23
Recruiting
AstraZeneca
Phase 1/2
85
Illinois, New York, North Carolina, Oregon, Texas
2026-01-09
Recruiting
A Study of AZD0120 in Autoimmune Diseases
NCT07295847Systemic Sclerosis, Idiopathic Inflammatory Myopathies, Rheumatoid Arthritis
AstraZeneca
Phase 1/2
27
Arizona, California, Florida, Illinois, Maryland, Michigan, Missouri, New York
2026-01-09
Recruiting
AstraZeneca
Phase 3
1,100
Alabama, Arkansas, California, District of Columbia, Florida, Illinois, Indiana, Kentucky
2025-12-29
Recruiting
AstraZeneca
Phase 2
320
Arizona, California, Colorado, Florida, Georgia, Illinois, Louisiana, Maryland
2025-12-15
Recruiting
AstraZeneca
Phase 2
230
Arizona, California, Connecticut, Florida, Georgia, Idaho, Illinois, Kentucky
2025-12-10
Recruiting
AstraZeneca
Phase 1
24
Arizona, Colorado, District of Columbia, Illinois, Missouri, New York, Ohio, Washington
2025-12-09
Active, closed
AstraZeneca
Phase 2
222
Arizona, Florida, Georgia, Illinois, Kansas, North Carolina, Ohio, Pennsylvania
2025-12-05
Recruiting
AstraZeneca
Phase 1/2
83
California, Florida, Illinois, Iowa, Tennessee, Texas
2025-11-12
Recruiting
AstraZeneca
Phase 3
400
Arizona, California, Colorado, Delaware, District of Columbia, Florida, Georgia, Illinois
2025-10-31
Recruiting
DESTINY-PANTUMOUR04
NCT07124000Adenocarcinoma (NOS), Anal Cancer, Bladder Cancer, Cervical Cancer
AstraZeneca
Observational
100
Alabama, Arizona, California, Colorado, Florida, Illinois, Kansas, New Mexico
2025-09-18
Active, closed
AstraZeneca
Phase 1/2
405
California, Florida, Georgia, Illinois, Kansas, Missouri, Nebraska, Nevada
2025-09-04
Active, closed
AstraZeneca
Phase 3
212
California, Connecticut, Illinois, Maryland, Massachusetts, Michigan, Minnesota, Mississippi
2025-08-07
Recruiting
AstraZeneca
Phase 3
700
Arizona, California, Colorado, Florida, Georgia, Illinois, Indiana, Maryland
2025-08-06
Recruiting
AstraZeneca
Phase 3
800
Arizona, California, District of Columbia, Florida, Hawaii, Illinois, Indiana, Maine
2025-08-01
Active, closed
A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With HeFH
NCT07000136Heterozygous Familial Hypercholesterolaemia
AstraZeneca
Phase 3
473
California, Florida, Georgia, Illinois, Louisiana, Nevada, New York, North Carolina
2025-06-10
Active, closed
AstraZeneca
Phase 3
3,103
Alabama, Arizona, California, Connecticut, Florida, Georgia, Illinois, Indiana
2025-05-28
Recruiting
AstraZeneca
Phase 1/2
150
California, Florida, Georgia, Illinois, Maryland, Massachusetts, Missouri, New York
2025-04-21
Recruiting
AstraZeneca
Phase 3
830
California, Delaware, Florida, Georgia, Illinois, Iowa, Kansas, Kentucky
2025-04-10
Recruiting
AstraZeneca
Phase 3
990
Alabama, Arizona, California, Connecticut, Delaware, Florida, Georgia, Illinois
2025-03-25
Recruiting
AstraZeneca
Phase 3
990
Alabama, Arizona, California, Florida, Georgia, Idaho, Illinois, Indiana
2025-03-18
Recruiting
AstraZeneca
Phase 1
136
California, Florida, Illinois, Louisiana, Massachusetts, Minnesota, Nebraska, New York
2025-03-10
Active, closed
AstraZeneca
Phase 2
63
Alabama, Arizona, California, Florida, Georgia, Illinois, Louisiana, Maryland
2025-03-05
Recruiting
AstraZeneca
Phase 3
840
Alaska, Arizona, California, Colorado, Delaware, Florida, Georgia, Illinois
2025-03-01
Active, closed
AstraZeneca
Phase 1/2
242
Alabama, California, Colorado, Florida, Georgia, Illinois, Iowa, Kentucky
2024-12-30
Active, closed
AstraZeneca
Phase 3
181
California, Illinois, Massachusetts, Missouri
2024-12-03
Recruiting
Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
NCT06526793B-cell Non-Hodgkin Lymphoma, Follicular Lymphoma (FL), Large B-Cell Lymphoma (LBCL)
AstraZeneca
Phase 2
270
Arizona, California, Florida, Illinois, Iowa, Kansas, Minnesota, Missouri
2024-11-27
Recruiting
AstraZeneca
Phase 3
620
Arizona, California, District of Columbia, Florida, Georgia, Idaho, Illinois, Maryland
2024-08-12
Active, closed
A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours
NCT06147037Advanced Solid Tumor, Metastatic Colorectal Carcinoma, Head and Neck Squamous Cell Carcinoma, Non-small Cell Lung Cancer
AstraZeneca
Phase 1
13
California, Illinois, Nebraska, Ohio, Texas, Washington
2024-07-31
Active, closed
AstraZeneca
Phase 3
339
Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Illinois, Indiana
2024-06-29
Recruiting
Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis
NCT06465810Transthyretin Amyloidosis, ATTR-CM, ATTRv-PN, ATTR
AstraZeneca
Observational
1,850
California, Connecticut, District of Columbia, Illinois, Indiana, Maryland, Massachusetts, Minnesota
2024-06-25
Recruiting
AstraZeneca
Phase 3
582
California, Connecticut, District of Columbia, Florida, Hawaii, Illinois, Indiana, Maryland
2024-04-29
Active, closed
AstraZeneca
Phase 3
4,005
Alabama, Arizona, Arkansas, California, Colorado, Florida, Georgia, Illinois
2024-04-12
Recruiting
AstraZeneca
Phase 3
675
Alaska, Arizona, Arkansas, California, Florida, Georgia, Illinois, Indiana
2024-04-11
Active, closed
Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
NCT06218914Non-small Cell Lung Cancer, Colorectal Carcinoma, Pancreatic Ductal Adenocarcinoma, Endometrial Cancer
AstraZeneca
Phase 1
108
California, Florida, Illinois, Kansas, Missouri, New York, Pennsylvania, Tennessee
2024-03-22
Recruiting
AstraZeneca
Phase 3
100
Arizona, California, District of Columbia, Florida, Illinois, Louisiana, Maryland, Minnesota
2024-03-14
Active, closed
AstraZeneca
Phase 2
58
Colorado, Florida, Georgia, Illinois, Massachusetts, Michigan, Missouri, New Jersey
2024-02-13
Recruiting
AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
NCT06137118B-cell Acute Lymphoblastic Leukemia (B-ALL)
AstraZeneca
Phase 1/2
255
Alabama, California, Florida, Georgia, Illinois, New York, Texas, Virginia
2023-12-29
Recruiting
Observational Study Protocol: LIVER-R
NCT06252753Hepatobiliary Cancers
AstraZeneca
Observational
4,000
Alabama, Arizona, California, Florida, Georgia, Illinois, Louisiana, Massachusetts
2023-12-20
Recruiting
AstraZeneca
Phase 3
1,145
Alabama, Arizona, Arkansas, California, Colorado, District of Columbia, Florida, Illinois
2023-12-14
Active, closed
AstraZeneca
Phase 3
760
Alabama, Arizona, California, Colorado, District of Columbia, Florida, Georgia, Illinois
2023-12-04
Active, closed
AstraZeneca
Phase 3
1,898
Arizona, Arkansas, California, Colorado, Connecticut, Georgia, Illinois, Indiana
2023-11-21
Active, closed
AstraZeneca
Phase 3
863
California, Colorado, Florida, Georgia, Illinois, Minnesota, Missouri, New York
2023-11-09
Active, closed
AstraZeneca
Phase 3
314
Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Illinois, Kansas
2023-11-08
Active, closed
AstraZeneca
Phase 3
1,835
Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Kentucky
2023-11-07
Recruiting
AstraZeneca
Phase 3
800
Alabama, Arizona, Arkansas, California, Georgia, Illinois, Indiana, Louisiana
2023-09-22
Recruiting
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
NCT05850234Relapsed/Refractory Multiple Myeloma
AstraZeneca
Phase 1/2
232
Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Iowa
2023-07-20
Active, closed
AstraZeneca
Phase 3
1,350
Arizona, Arkansas, California, Colorado, Florida, Illinois, Indiana, Iowa
2022-12-29
Active, closed
First in Human Study of AZD9592 in Solid Tumors
NCT05647122Advanced Solid Tumours, Carcinoma Non-small Cell Lung, Head and Neck Neoplasms, Colorectal Neoplasms
AstraZeneca
Phase 1
190
California, Connecticut, District of Columbia, Illinois, Maryland, Massachusetts, New York, Pennsylvania
2022-12-21
Active, closed
AstraZeneca
Phase 3
368
Arizona, Arkansas, California, Colorado, Florida, Illinois, Iowa, Kansas
2022-11-10
Recruiting
AstraZeneca
Phase 1/2
695
California, Illinois, Massachusetts, New York, Oregon, Texas, Virginia
2022-06-24
Recruiting
AstraZeneca
Phase 2
630
Arkansas, California, Connecticut, Florida, Georgia, Illinois, Maryland, Massachusetts
2022-04-14
Active, closed
AstraZeneca
Phase 3
390
Alaska, California, Colorado, Delaware, Georgia, Illinois, Maryland, New Jersey
2022-02-21
Active, closed
AstraZeneca
Phase 3
791
Arizona, California, District of Columbia, Florida, Georgia, Illinois, Kentucky, Maryland
2022-02-18
Active, closed
AstraZeneca
Phase 3
1,051
California, Connecticut, Florida, Illinois, Indiana, Kentucky, Maryland, Michigan
2022-02-07
Active, closed
AstraZeneca
Phase 1/2
212
Illinois, Minnesota, Virginia
2021-09-14
Active, closed
AstraZeneca
Phase 3
712
California, Connecticut, District of Columbia, Florida, Idaho, Illinois, Indiana, Iowa
2021-08-05
Active, closed
AstraZeneca
Phase 3
315
Arizona, Arkansas, California, Colorado, Florida, Georgia, Illinois, Indiana
2021-06-30
Active, closed
AstraZeneca
Phase 3
370
Arizona, Illinois, Kansas, Massachusetts, Michigan, Minnesota, Missouri, Nevada
2020-10-02
Active, closed
A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors
NCT04482309Part 1: Bladder, Biliary Tract, Cervical, Endometrial, Ovarian, Pancreatic Cancer, Rare Tumors, Any Tumor Type Excluding Breast, Gastric, Colorectal Cancer, Part 2: HER2 Expressing/Amplified Solid Tumors Excluding Breast, Gastric, Colorectal Cancer
AstraZeneca
Phase 2
477
California, Illinois, Indiana, Massachusetts, New Jersey, New York, North Carolina, Texas
2020-08-18
Active, closed
AstraZeneca
Phase 3
1,012
Arizona, California, Colorado, Connecticut, Florida, Illinois, Maryland, Michigan
2020-07-13
Active, closed
AstraZeneca
Phase 3
805
Arizona, California, Colorado, Florida, Georgia, Hawaii, Illinois, Indiana
2020-05-05
Active, closed
AstraZeneca
Phase 3
923
California, Florida, Illinois, Kansas, Maryland, Michigan, New York, Ohio
2019-06-25
Active, closed
AstraZeneca
Phase 2
247
California, Connecticut, Illinois, Maryland, Massachusetts, Michigan, New York, Oregon
2019-06-25
Active, closed
AstraZeneca
Phase 3
724
Alabama, Arizona, California, Delaware, District of Columbia, Florida, Georgia, Illinois
2019-03-06
Active, closed
AstraZeneca
Phase 3
1,407
California, Florida, Georgia, Illinois, Indiana, Maryland, Michigan, Missouri
2019-01-04
Active, closed
AstraZeneca
Phase 3
825
Arizona, California, Colorado, Florida, Illinois, Kansas, Kentucky, Maryland
2018-12-06
Active, closed
AstraZeneca
Phase 3
724
California, District of Columbia, Florida, Hawaii, Illinois, Louisiana, Michigan, Minnesota
2018-11-30
Active, closed
AstraZeneca
Phase 3
1,063
Alabama, California, Connecticut, Illinois, Iowa, Kansas, Kentucky, Louisiana
2018-11-16
Active, closed
AstraZeneca
Phase 3
895
Alabama, Alaska, Arizona, California, Colorado, Illinois, Indiana, Louisiana
2018-10-31
Active, closed
AstraZeneca
Phase 3
730
Arizona, California, Connecticut, Florida, Georgia, Illinois, Indiana, Kentucky
2018-09-27
Active, closed
AstraZeneca
Phase 3
1,246
Alabama, California, Connecticut, District of Columbia, Florida, Illinois, Indiana, Kansas
2018-09-27
Active, closed
AstraZeneca
Phase 2
273
Alabama, Alaska, Arizona, Colorado, Connecticut, Illinois, Indiana, Kentucky
2018-03-07
Active, closed
AstraZeneca
Phase 2
528
California, District of Columbia, Illinois, Maryland, Massachusetts, Missouri, New York, Pennsylvania
2017-12-18
Active, closed
Savolitinib vs. Sunitinib in MET-driven PRCC.
NCT03091192Carcinoma, Carcinoma, Renal Cell, Kidney Neoplasms, Urologic Neoplasms
AstraZeneca
Phase 3
60
California, Georgia, Illinois, Iowa, Massachusetts, Missouri, New York, Tennessee
2017-07-25
Active, closed
AstraZeneca
Phase 3
682
California, Colorado, Connecticut, Florida, Georgia, Hawaii, Illinois, Maryland
2015-10-21
Active, closed
AstraZeneca
Phase 3
510
Colorado, Florida, Georgia, Illinois, Louisiana, Massachusetts, New York, North Carolina
2013-09-25
Active, closed
Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy
NCT01874353Platinum Sensitive, BRCA Mutated, Relapsed Ovarian Cancer, Following Complete or Partial Response to Platinum Based Chemotherapy
AstraZeneca
Phase 3
327
Alabama, California, Colorado, Connecticut, Florida, Illinois, Maryland, Massachusetts
2013-09-03
Active, closed
AstraZeneca
Phase 3
736
Arizona, California, Connecticut, Florida, Illinois, Maryland, Michigan, Missouri
2005-02-13
Rows per page Showing 1–109 of 109
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 21 November 2026. https://priyalifescience.com/clinical-trials-usa/state/illinois

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the US and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,148 studies in total at the last sync on 21 Nov 2026, 03:16 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 109 of those studies with a site in Illinois that also match the filters currently applied.

How many clinical trials are recruiting in Illinois?

56 of the 109 studies on this page are recruiting new participants as of the 21 Nov 2026, 03:16 UTC sync. A further 1 have not yet opened recruitment, 52 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Illinois), 109 studies
PhaseStudiesRecruitingShare
Phase 3713565.1%
Phase 215513.8%
Phase 1/211710.1%
Phase 1635.5%
Observational554.6%
Phase 4110.9%

Most active sponsors

Lead sponsors with the most studies (Illinois)
Lead sponsorStudiesRecruiting
AstraZeneca10956
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.